Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 15/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL302389 | 0.91 | BDKRB1 (0.47) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL12346701 | 0.90 | BDKRB1 (0.51) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL2240006 | 0.90 | BDKRB1 (0.56) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| Trifluoroacetic Acid SCHEMBL302857 | 0.84 | BDKRB1 (0.45) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL2237280 | 0.83 | BDKRB1 (0.57) | BDKRB1 | |
| SCHEMBL12346726 | 0.82 | BDKRB1 (0.49) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL2237830 | 0.81 | BDKRB1 (0.48) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL2238643 | 0.80 | BDKRB1 (0.47) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| Trifluoroacetamide SCHEMBL2238139 | 0.80 | BDKRB1 (0.45) | BDKRB1MEN1KMT2ARAB9AMAPT | |
| Trifluoroacetic Acid SCHEMBL2241929 | 0.80 | BDKRB1 (0.39) | BDKRB1MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | claimed |
| JP-2012500783-A | — | — | 2012-01-12 | — | — | JP | claimed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | claimed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | claimed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | BDKRB1 1/4885MEN1 231/4885KMT2A 1859/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | BDKRB1 1/4885MEN1 349/4885KMT2A 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.